Insight Molecular Diagnostics Inc (IMDX)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$4.13+0.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · IMDX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 229.0% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -60.0% |
Growth built into the price is above our model estimate.
The price assumes 289.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 32 industry peers · Company calendar date is not available
IMDX — earnings in line
Dated 2026-08-10
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless…
Why it matters: Large orders show strong demand for GraftAssureDx. This proves the product's market potential.
Supportive ifReceipt of U.S. orders exceeding $1 million within three months of FDA approval.
Worry ifNo significant U.S. orders within three months of FDA approval.
Why it matters: High cash burn can threaten the company's financial stability and growth plans.
Worry ifQuarterly cash burn reported at or below $6M.
Less concerning ifCash burn remains above $7M for two consecutive quarters.
Why it matters: Getting this approval is key for the company's growth and entering the market.
Supportive ifThe company announced it got approval to market its product.
Worry ifNo updates or delays in the approval process are reported.
Why it matters: If healthcare revenue growth speeds up, it may mean a better time for IMDX.
Watch forHealthcare sector revenue growth speeds up to 10% or more.
Also watch forHealthcare revenue growth keeps slowing down below 10%.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$238 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $1,004 loss on $10,000 · 10.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,993 loss on $10,000 · 69.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: More transplant centers in the study can boost credibility and market reach.
Supportive ifEnrollment reaches 50 U.S. transplant centers for the GALACTIC study.
Worry ifEnrollment stays below 34 centers for the GALACTIC study.
Why it matters: First major U.S. orders would signal market acceptance and demand for the product.
Supportive ifA big U.S. transplant hospital orders GraftAssureIQ.
Worry ifNo significant U.S. orders of GraftAssureIQ by the end of Q2 2026.
Why it matters: New research can show GraftAssure works and attract more interest.
Supportive ifAt least one new study shows GraftAssure technology is effective.
Worry ifNo new studies on GraftAssure technology in the next six months.
Why it matters: Expanding into heart transplant testing could broaden the market for GraftAssureDx. This would enhance growth prospects.
Watch forThere is news of good heart transplant test results with GraftAssureDx.
Also watch forNo progress or bad results in heart transplant tests with GraftAssureDx.
Why it matters: Good talks with the FDA are important for quick approval of GraftAssureDx.
Watch forManagement says talks with the FDA are going well without major issues.
Also watch forManagement reports serious problems or delays in talks with the FDA.
Why it matters: This agreement can increase revenue and support the company's growth plan.
Supportive ifA press release tells about the first successful collection of specimens.
Worry ifNo updates or delays in the agreement with Quest Diagnostics.
Why it matters: Gaining FDA approval is crucial for commercial sales of GraftAssureDx. It will open the market for the product.
Supportive ifFDA approves GraftAssureDx on time in late 2026.
Worry ifFDA delays approval past 2026 or asks for more data.
Why it matters: Good payment policies can increase demand for GraftAssureDx. This affects lab use of the test.
Supportive ifMedicare expands payments for dd-cfDNA testing, leading to more tests.
Worry ifMedicare cuts or limits payments for dd-cfDNA testing.
Why it matters: Big orders after approval would show demand for GraftAssureDx. This would increase revenue.
Supportive ifMajor U.S. transplant centers place orders for GraftAssureDx kits shortly after FDA approval.
Worry ifNo big orders come in three months after FDA approval.